Swiss Multicenter Ab Interno XEN45 Gel Stent Study: 2-Year Real-World Data.

Autor: Papazoglou A; Department of Ophthalmology, Cantonal Hospital Aarau, Aarau, Switzerland. anthia.papazoglou@gmail.com.; Medical Faculty, University of Zurich, Zurich, Switzerland. anthia.papazoglou@gmail.com., Höhn R; Department of Ophthalmology, University Hospital Bern, Bern, Switzerland.; Eyeparc Eyeclinic, Bern, Switzerland., Schawkat M; Department of Ophthalmology, University Hospital Bern, Bern, Switzerland., Tappeiner C; Department of Ophthalmology, University Hospital Bern, Bern, Switzerland.; Department of Ophthalmology, Pallas Kliniken, Olten, Switzerland.; Medical Faculty, University of Bern, Bern, Switzerland.; Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Iliev M; Department of Ophthalmology, University Hospital Bern, Bern, Switzerland.; Medical Faculty, University of Bern, Bern, Switzerland., Gugleta K; Department of Ophthalmology, University of Basel and University Hospital, Basel, Switzerland., Saletta G; Department of Ophthalmology, University of Basel and University Hospital, Basel, Switzerland., Wiencierz A; Department of Clinical Research, University of Basel and University Hospital, Basel, Switzerland., Wagels B; Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Todorova MG; Medical Faculty, University of Zurich, Zurich, Switzerland.; Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Krzyzanowska I; Medical Faculty, University of Zurich, Zurich, Switzerland.; Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland., Töteberg-Harms M; Medical Faculty, University of Zurich, Zurich, Switzerland.; Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.; Department of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA, USA., Tschopp M; Department of Ophthalmology, Cantonal Hospital Aarau, Aarau, Switzerland. markus.tschopp@windowslive.com.; Medical Faculty, University of Bern, Bern, Switzerland. markus.tschopp@windowslive.com.
Jazyk: angličtina
Zdroj: Ophthalmology and therapy [Ophthalmol Ther] 2024 Jun; Vol. 13 (6), pp. 1513-1525. Date of Electronic Publication: 2024 Apr 06.
DOI: 10.1007/s40123-024-00917-y
Abstrakt: Introduction: The aim of this study was to investigate the 2-year postoperative efficacy of the XEN45 Gel Stent by evaluating the reduction of intraocular pressure (IOP) and the need for eye pressure-lowering medications in a multicenter setting in Switzerland.
Methods: Patients with various types of glaucoma who received a XEN45 Gel Stent with or without combined phacoemulsification cataract surgery at five hospitals in Switzerland were retrospectively enrolled. Pre- and postoperative IOP, the number of antiglaucoma medications, and the need of subsequent interventions to control IOP were assessed. The success rate was defined as a ≥ 20% reduction of IOP 2 years postoperatively without the need for subsequent glaucoma surgery.
Results: A total of 345 eyes were included: 44.3% with primary open-angle, 42.0% pseudoexfoliation, and 13.7% with other types of glaucoma. Of these, 206 patients were followed for 2 years. Preoperatively, the mean IOP was 26.3 ± 8.9 mmHg and the mean number of antiglaucoma medications administered was 3.0 ± 1.3. Two years postoperatively, the success rate was 66.0% (95% confidence interval 59.3-72.1%), the IOP had dropped by 43.8% to 14.8 ± 5.7 mmHg, and the number of medications was reduced by a mean of 2.0 ± 1.7 per day. Postoperative complications and the need for interventions remained low.
Conclusion: The XEN45 Gel Stent successfully reduced IOP and the number of antiglaucoma drugs in most patients at 2 years postoperatively.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje